Oncology News and Research

RSS
ERYTECH reports fast take-off of GRASPA Phase IIb trial in patients with acute myeloid leukemia

ERYTECH reports fast take-off of GRASPA Phase IIb trial in patients with acute myeloid leukemia

MGN1703 drug provides a new treatment approach to colorectal cancer

MGN1703 drug provides a new treatment approach to colorectal cancer

Adding chemotherapy after surgery for patients with advanced gastric cancer can reduce mortality risk

Adding chemotherapy after surgery for patients with advanced gastric cancer can reduce mortality risk

Study shows miR-22 plays a key role in breast and blood cancers

Study shows miR-22 plays a key role in breast and blood cancers

Discovery sheds new light on aggressiveness of certain breast cancers

Discovery sheds new light on aggressiveness of certain breast cancers

Research shows over 50% of tumors have mutations in p53

Research shows over 50% of tumors have mutations in p53

Wake Forest Baptist to extend innovation in geriatrics education with new GPS program

Wake Forest Baptist to extend innovation in geriatrics education with new GPS program

CTI announces publication of preclinical, clinical data for pacritinib in Drugs of the Future 2013

CTI announces publication of preclinical, clinical data for pacritinib in Drugs of the Future 2013

Array BioPharma achieves milestone for initiation of MEK162 Phase 3 trial in patients with LGSOC

Array BioPharma achieves milestone for initiation of MEK162 Phase 3 trial in patients with LGSOC

Prosigna Breast Cancer Prognostic Gene Signature Assay study published in JCO

Prosigna Breast Cancer Prognostic Gene Signature Assay study published in JCO

VIZZIA Technologies' clinical workflow optimization solution installed at FCS Tampa Cancer Center

VIZZIA Technologies' clinical workflow optimization solution installed at FCS Tampa Cancer Center

ARIAD Pharmaceuticals' Iclusig gets EC marketing authorization for CML and Ph+ ALL treatment

ARIAD Pharmaceuticals' Iclusig gets EC marketing authorization for CML and Ph+ ALL treatment

Research roundup: 'Welcome-mat' effect of Medicaid expansion; Setting up shops; California's transition to Medicaid managed care

Research roundup: 'Welcome-mat' effect of Medicaid expansion; Setting up shops; California's transition to Medicaid managed care

UH and Case Western Reserve University to develop diagnostic tests to determine HIV drug resistance

UH and Case Western Reserve University to develop diagnostic tests to determine HIV drug resistance

Study shows that PCCs can reverse blood thinning effects of XARELTO in healthy subjects

Study shows that PCCs can reverse blood thinning effects of XARELTO in healthy subjects

UNC scientists use GEMMs to develop biomarkers for molecular subtypes of human breast cancer

UNC scientists use GEMMs to develop biomarkers for molecular subtypes of human breast cancer

ALK immunocytochemistry accurately detects NSCLC on cytological specimens

ALK immunocytochemistry accurately detects NSCLC on cytological specimens

Researchers use two new methods to detect levels of ALK protein expression in NSCLC

Researchers use two new methods to detect levels of ALK protein expression in NSCLC

SBRT treatment safe and effective for stage I NSCLC, study finds

SBRT treatment safe and effective for stage I NSCLC, study finds

Bayer, Onyx submit sNDA to FDA, marketing authorization application to EMA for Nexavar tablets

Bayer, Onyx submit sNDA to FDA, marketing authorization application to EMA for Nexavar tablets

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.